Allegato B

MARCO LUCARELLI

Curriculum Vitae

Part I – General Information

Full Name	Marco Lucarelli
Position title	Associate Professor of Clinical Biochemistry and Clinical Molecular Biology at Department of Experimental Medicine of Sapienza University of Rome, Italy
Date of Birth	
Place of Birth	
Citizenship	
Permanent Address	
Mobile Phone Number	
E-mail	
Languages	Mother tongue: Italian. Other language: English (Understanding - listening C1, reading C2; Speaking - spoken interaction C1, spoken production C2; Writing C2). Other language: French (school level).

Part II – Education/Training

INSTITUTION AND LOCATION	DEGREE	COMPLETION DATE	FIELD OF STUDY
Medical Faculty of the Sapienza University of Rome, Italy	Degree of Specialist in Clinical Pathology, 70/70 cum laude	1992	Clinical Pathology and Clinical Molecular Biology
Sapienza University of Rome, Italy	Professional qualification as Biologist	1988	Biology
Science Faculty of the Sapienza University of Rome, Italy	Graduation in Biological Sciences, 110/110 cum laude	1986	Biology
Ministry of education	High school scientific diploma	1980	Science
- Dept. of Cellular Biotechnologies and Hematology of the Medical Faculty, Sapienza University of Rome, Italy - Dept. of Biopathology of the Medical Faculty, University of Rome "Tor Vergata", Italy - Dept. of Genetics and Molecular Biology of the Science Faculty, Sapienza University of Rome, Italy	Research fellow, contractor and assistant researcher	1986 - 1999	Biology, Clinical Biochemistry and Clinical Molecular Biology

Part III – Appointments

START	END	INSTITUTION	POSITION
2005	at present	Medical Faculty of the Sapienza University of Rome	Associate Professor of Clinical biochemistry and clinical molecular biology (from 2018 November 1st at Dept. of Experimental Medicine; up to 2018 October 31st at Dept. of Cellular Biotechnologies and Hematology)
2018 June 1st	at present	Policlinico Umberto I University Hospital (AOU Policlinico Umberto I)	Head of the automated Central Laboratory (UOS Laboratorio Centrale)
2019 December 11th	at present	Dept. of Experimental Medicine, Sapienza University of Rome	Participation to university governance: Member of the Board of the Department *(Giunta di Dipartimento)*
2009	at present	Italian Pasteur Institute Cenci Bolognetti Foundation	Formal research appointments
2017	at present	Medicine and Surgery degree, Sapienza University of Rome	President of the integrated course of Laboratory Medicine (channel A)
2016	at present	Medical Molecular Biotechnologies degree, Sapienza University of Rome	President of the integrated course of Laboratory, Molecular and Imaging Diagnostics
2014	at present	Italian Institute of Health (ISS)	Assessor in the control quality national scheme for the cystic fibrosis genetic test
2017	2022	Italian Cystic Fibrosis Society (SIFC)	National coordinator of the research commission
1999	2004	Dept. of Cellular Biotechnologies and Hematology of the Sapienza University of Rome	Researcher *(RU)* of Clinical biochemistry and clinical molecular biology
1999	2018 May 31st	Policlinico Umberto I University Hospital (AOU Policlinico Umberto I)	Affiliated to the University Hospital as executive in the Central Laboratory *(strutturazione assistenziale come Dirigente di I livello)*
2014	2016	Italian Cystic Fibrosis Society (SIFC)	National coordinator of the cystic fibrosis geneticist group
2017	2018 October 31st	Medical Faculty of the Sapienza University of Rome	Participation to university governance: Member of the Board of the Medical Faculty *(Giunta di Facoltà)*
2017	2018 October 31st	Dept. of Cellular Biotechnologies and Hematology of the Sapienza University of Rome	Participation to university governance: Member of the Board of the Department *(Giunta di Dipartimento)*
2016	2019	Italian Cystic Fibrosis Society (SIFC)	Coordinator of the working group for the revision of Consensus document on the cystic fibrosis genetic analysis

Main activities and responsibilities: teaching, research and clinical support.

Part IV – Teaching experience

The teaching activity has been performed since 1989 in over 20 different courses.

Currently, regular teacher of the following 9 courses of the Sapienza University of Rome:

- Laboratory, molecular and imaging diagnostics (Medical Biotechnologies degree), since 2004; ***President of the integrated course.***
- Clinical biochemistry and clinical molecular biology (Laboratory Medicine course, Medicine and Surgery degree; channel A) since 2017; ***President of the integrated course.***
- Clinical biochemistry and clinical molecular biology (Laboratory Medicine and Advanced Technologies course, Medicine and Surgery High Technology degree), since 2022.
- Clinical biochemistry and clinical molecular biology (Laboratory Medicine course, Medicine and Surgery degree; channel B), since 2019.
- Clinical biochemistry and clinical molecular biology (Laboratory Medicine course, Medicine and Surgery degree; channel C), since 2010.
- Molecular biology (Biochemical Bases of Diagnostic Sciences course, Biomedical Laboratory Techniques degree), since 2017.
- Clinical biochemistry (Specialization School in Hematology), since 2009.
- Clinical biochemistry (Specialization School in Clinical Pathology and Clinical Biochemistry), since 2017.
- Clinical biochemistry (Specialization School in Microbiology and Virology), since 2018.

Member of the teaching staff of the:

- Doctorate in Human Biology and Medical Genetics of the Dept. of Molecular Medicine of the Sapienza University of Rome;
- Laboratory Medicine School, Clinical molecular biology course, of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBIOC) (from 2010 to 2015).

For further details about teaching activity, also about courses held in the past, see the declarations about teaching at the online page 3/5.

Part V – Policlinico Umberto I University Hospital: clinical support activity and management commitments

Medical laboratory responsibility and organization: Head of the automated core laboratory and specialized sections of the Central Laboratory of the Policlinico Umberto I University Hospital (***Responsabile UOS Laboratorio Centrale, AOU Policlinico Umberto I***), since 1st June 2018.

Specialized clinical support activity: molecular diagnostics of cystic fibrosis (CFTR gene); molecular diagnostics of low HDL syndrome (ApoA1, LCAT, LPL, ABCA1 genes); molecular diagnostics of alcohol addiction (5-HTT, OPRM1 genes).

Management commitments: President of the tender committee for the automated laboratory equipment and reagents for the diagnostic activity of the Clinical Pathology area of the Policlinico Umberto I University Hospital (resolution of the General Director n. 0000062 29th January 2024).

Documentazione in file allegato in Titoli N. 7

Part VI - Memberships, awards, honors, patents, activity as reviewer, editorial board, commitment in national and international congresses

Patents – National patent holder of a method of mutational search in the CFTR gene based on the primer extension principle (Brevetto N. 0001371810). *Documentazione in file allegato in Titoli N. 2*

Reviewer for scientific journals - Peer reviewer of the following 27 scientific journals: Annali Istituto Superiore di Sanità; Annals of Human Genetics; Biofactors; Bioinformatics and Biology Insights - SAGE Journal; BioTechniques; BMC Medical Genomics; Clinical Genetics; Disease Markers; Epigenetics; Expert Review of Respiratory Medicine; Fertility and Sterility; Genetics and Molecular Biology; Heliyon; Internal Medicine Journal; International Journal of Neonatal Screening; Journal of Clinical Medicine; Journal of Cystic Fibrosis; Journal of Human Genetics; Journal of Medical Genetics; Journal of Molecular Medicine; Molecular Therapy Nucleic Acids; OMICS Publishing – ACR GROUP (General Medicine); Organisms, Journal of Biological Sciences; Panminerva Medica; PLOS one; World Journal of Gastroenterology; World Journal of Hepatology.

Reviewer for funding bodies - External reviewer for the Italian Cystic Fibrosis Foundation (FFC).

Editorial board - Associate Editor of the following 4 scientific journals: World Journal of Medical Genetics (since 2011); AIMS Medical Science (since 2016); BMC Medical Genomics (since 2019); Journal of Personalized Medicine (since 2024).

Memberships of scientific societies - Member of the: Epigenetics Society (ES); European Cystic Fibrosis Society (ECFS); Italian Cystic Fibrosis Society (SIFC); Italian Clinical Biochemistry and Clinical Molecular Biology Society (SIBIOC); Italian Human Genetics Society (SIGU).

Organizing committee of international congresses - Member of the organizing committee of the 1st epigenetics society (ES) international meeting on "Epigenetics of disease and development" (12-14 October 2023, Rome, Italy). *Documentazione in file allegato in Titoli N. 3*

Moderator, reviewer and chair in international congresses – Moderator, reviewer and chair in the European Young Investigator Meeting (EYIM) (21st - 23rd February 2018, Paris, France).
Documentazione in file allegato in Titoli N. 4

Organizing committee of national congresses and courses
- Member of the organizing committee of the XXIII Congresso Italiano Fibrosi Cistica (22th - 25th November 2017, Naples, Italy) *Documentazione in file allegato in Titoli N. 5*
- Member of the organizing committee of the course on Appropriatezza dei test genetici: il Documento Consensus per l'analisi genetica in Fibrosi Cistica (18th September 2018, Rome, Italy)
Documentazione in file allegato in Titoli N. 6

Coordination of committees, study groups, working groups and moderation – Carrying out this kind of tasks from 2016 to 2024 in 22 different national congresses and meetings.

Speaker - From 2006 to 2024 oral communications in 21 different national congresses and meetings.

Part VII - Funding Information [grants as P.I. (principal investigator) or partner]

P.I. or Partner in over 30 funded projects for a total value of over 1 000 000 euros. Most recent grants funded as P.I. or Partner are reported in the following, with indicated the **coordination of 6 and the participation as partner in 3, multicenter national scientific projects.**

Period: from January 2024 to December 2024. Amount: 10.603 euros.
Project Title: The role of CFTR and FOXI1 genes in respiratory epithelium differentiation and precision therapy of Cystic Fibrosis. Granting Agency: Sapienza University of Rome. Role: P.I.

Period: from January 2024 to December 2024. Amount: 60.000 euros.
Project Title: Analysis of gene variants and epigenetic patterns by sequencing, in pathologies with altered gene expression (call for University equipment). Granting Agency: Sapienza University of Rome. Role: Partner.

Period: from October 2023 to September 2025. Amount: 214.420 euros.
Project Title: Theratyping of Cystic Fibrosis.
Granting Agency: Italian Ministry of University and Research (program "Research Projects of National Interest", PRIN 2022). Code: CUP B53D23020270006. The project is in collaboration with the University of Verona and the University of Naples "Federico II". Role: P.I.
Coordination of a multicenter national scientific project.

Period: from January 2022 to December 2023. Amount: 40.000 euros.
Project Title: The personalized therapy of Cystic Fibrosis by theratyping and gene targeting.
Granting Agency: Pasteur Italian Institute - Fondazione Cenci Bolognetti. The project is in collaboration with the Italian Institute of Health (ISS). Role: P.I.
Coordination of a multicenter national scientific project.

Period: from September 2021 to August 2023. Amount: 129.800 euros.
Project Title: Theratyping of Cystic Fibrosis.
Granting Agency: Italian Cystic Fibrosis Foundation. Code: FFC#8/2021. The project is in collaboration with the Italian Institute of Health (ISS). Role: P.I.
Coordination of a multicenter national scientific project.

Period: from January 2023 to December 2023. Amount: 10.000 euros.
Project Title: Theratyping and epigenetic targeting of CF
Granting Agency: Sapienza University of Rome. Role: P.I.

Period: from January 2022 to December 2022. Amount: 10.000 euros.
Project Title: Precision therapy of Cystic Fibrosis.
Granting Agency: Sapienza University of Rome. Role: P.I.

Period: from January 2021 to December 2021. Amount: 10.000 euros.
Project Title: The personalized therapy of Cystic Fibrosis by theratyping and gene targeting.
Granting Agency: Sapienza University of Rome. Role: P.I.

Period: from September 2020 to August 2021. Amount: 13.000 euros.
Project Title: Establishment of Conditionally Reprogrammed Airway Epithelial Stem Cell cultures from nasal epithelia of Cystic Fibrosis patients: exploring response to CFTR-modulating drugs for correlation with genetic profile (theratyping) and restoring CFTR function through gene editing approaches (1-year extension).
Granting Agency: Italian Cystic Fibrosis Foundation. Code: FFC#12/2018 extension. Role: Partner. The project was in collaboration with the Italian Institute of Health (ISS).
Participation in a multicenter national scientific project.

Period: from January 2020 to December 2020. Amount: 10.000 euros.
Project Title: Application of gene targeting by Small Fragment Homologous Replacement (SFHR) to human Cystic Fibrosis stem-like and differentiated cellular systems.
Granting Agency: Sapienza University of Rome. Role: P.I.

Period: from January 2020 to December 2020. Amount: 75.000 euros.
Project Title: Molecular mechanisms of transcriptional regulation of the serotonin transporter and their impact on alcohol dependence (call for University equipment).
Granting Agency: Sapienza University of Rome. Role: Partner.

Period: from September 2018 to August 2020. Amount: 29.500 euros.
Project Title: Establishment of Conditionally Reprogrammed Airway Epithelial Stem Cell cultures from nasal epithelia of cystic fibrosis patients: exploring response to CFTR-modulating drugs for correlation with genetic profile (theratyping) and restoring CFTR function through gene editing approaches.

Granting Agency: Italian Cystic Fibrosis Foundation. Code: FFC#12/2018. Role: Partner. The project was in collaboration with the Italian Institute of Health (ISS).
Participation in a multicenter national scientific project.

Period: from January 2019 to December 2019. Amount: 10.000 euros.
Project Title: Application of a gene targeting strategy to a mouse reporter system and to stem-induced human primary Cystic Fibrosis epithelial cells.
Granting Agency: Sapienza University of Rome. Role: P.I.

Period: from January 2018 to December 2018. Amount: 31.750 euros.
Project Title: Gene targeting by Small Fragment Homologous Replacement (SFHR): application to mouse reporter and human disease cellular systems.
Granting Agency: Sapienza University of Rome. Role: P.I.

Period: from January 2017 to December 2017. Amount: 13.000 euros.
Project Title: Gene targeting by Small Fragment Homologous Replacement (SFHR): the influence of epigenetics, DNA repair, cell cycle and CRISPR/Cas 9 approach.
Granting Agency: Sapienza University of Rome. Role: P.I.

Period: from January 2016 to December 2016. Amount: 4.000 euros.
Project Title: The role of intragenic variability of CFTR in different forms of cystic fibrosis.
Granting Agency: Sapienza University of Rome. Role: P.I.

Period: from January 2015 to December 2015. Amount: 5.000 euros.
Project Title: The role of complex alleles and haplotypes of CFTR in different clinical forms of cystic fibrosis.
Granting Agency: Sapienza University of Rome. Role: P.I.

Period: from January 2013 to December 2015. Amount: 60.000 euros.
Project Title: The influence of epigenetics, DNA repair and cell cycle pathways on the gene therapy approach of Small Fragment Homologous Replacement (SFHR).
Granting Agency: Italian Pasteur Institute - Fondazione Cenci Bolognetti. Role: P.I. The project was in collaboration with the University of Tor Vergata.
Coordination of a multicenter national scientific project.

Period: from January 2014 to December 2014. Amount: 7.000 euros.
Project Title: The analysis of the CFTR mutational pattern in different forms of cystic fibrosis: the genotype – phenotype relationship and its influence on the genetic test.
Granting Agency: Sapienza University of Rome. Role: P.I.

Period: from September 2012 to November 2014. Amount: 85.000 euros.
Project Title: Study of the pathogenetic and therapeutic role of the Epithelial Na+ channel (ENaC) in CF and CF-like disease.
Granting Agency: Italian Cystic Fibrosis Foundation. Code: FFC#3/2012. Role: P.I. The project was in collaboration with the University of Verona and the University of Foggia.
Coordination of a multicenter national scientific project.

Period: from January 2013 to December 2013. Amount: 7.000 euros.
Project Title: Cystic fibrosis: the complexity of a monogenic disease.
Granting Agency: Sapienza University of Rome. Role: P.I.

Period: from July 2009 to December 2012. Amount: 70.000 euros.
Project Title: The interplay between epigenetics, cell cycle and homologous recombination in the gene therapy by Small Fragment Homologous Replacement (SFHR).
Granting Agency: Italian Pasteur Institute - Fondazione Cenci Bolognetti. Role: P.I. The project was in collaboration with the University of Tor Vergata.
Coordination of a multicenter national scientific project.

Period: from September 2010 to August 2011. Amount: 22.000 euros.
Project title: Molecular and biological study of ENaC in CF and CF-like disease.
Granting Agency: Italian Cystic Fibrosis Foundation. Code: FFC#1/2010. Role: Partner. The project was in collaboration with University of Verona, University of Foggia and Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano.
Participation in a multicenter national scientific project.

Part VIII – Research activities

Leader of a research group with an extensive and consolidated network of **national and international scientific collaborations,** as documented by the list of co-authors and their affiliations reported in the collaborative publications produced.

The principal research lines pursued are the following:

- Precision therapy and theratyping of cystic fibrosis
- Molecular genetics of cystic fibrosis and of CFTR (cystic fibrosis transmembrane conductance regulator) related disorders (CFTR-RD) and study of the genotype/phenotype relationship in these diseases
- Functional characterization of CFTR and ENaC (epithelial sodium channel) genes in physiologic and pathologic conditions
- Molecular mechanisms of the gene therapy by small fragment homologous replacement (SFHR)
- DNA methylation, modulation of gene expression and cell differentiation
- Regulation of DNA methylation and demethylation processes in eukaryotic cells
- Molecular and pathogenetic mechanisms, and diagnostic methodologies underlying cystic fibrosis, CFTR-RD, atherosclerosis, alcohol addiction and neurological disorders
- Setup and automation of mutational search methodologies.

Part IX – Summary of overall scientific achievements (indicators)

Overall number of papers (from Scopus DB)	97
Number of international papers (from Scopus DB)	93
Number of national papers (from Scopus DB)	4
Number of books	1
Number of popular articles, comments, book chapters	10
Overall impact factor (from Journal Citation Reports (JCR) DB)	385
Average impact factor per paper (calculated from Journal Citation Reports (JCR) DB)	4.0
Total citations (from Scopus DB)	2016
Average citations per paper (calculated from Scopus DB)	20.8
Hirsch (H) index (from Scopus DB)	26
Normalized Hirsch (H) index (H index calculated from Scopus DB divided by the academic seniority)	0.9

Part X – Summary of scientific achievements (indicators) of the last 10 years (according to Art. 1 of the procedure)

Overall number of papers (from Scopus DB)	67
Number of international papers (from Scopus DB)	64
Number of national papers (from Scopus DB)	3
Number of books	1
Number of popular articles, comments, book chapters	3
Overall impact factor (from Journal Citation Reports (JCR) DB)	297
Average impact factor per paper (calculated from Journal Citation Reports (JCR) DB)	4.4
Total citations (from Scopus DB)	1067
Average citations per papers (calculated from Scopus DB)	15.9
Hirsch (H) index (from Scopus DB)	19
Normalized Hirsch (H) index (H index calculated from Scopus DB divided by the academic seniority of last 10 years	1.7

Part XI – Selected Publications

List of the 16 publications in international journals with IF > 3, in the time frame provided by the Art. 1 of the procedure (last 10 years), selected for the merit evaluation (publications of the last 5 years included), numbered from 1 to 16 (same numbers of the online list)

1) Orticello M., Cavallaro R.A., Antinori D., Raia T., **Lucarelli M.**, Fuso A.
Amyloidogenic and neuroinflammatory molecular pathways are contrasted using menaquinone 4 (MK4) and reduced menaquinone 7 (MK7R) in association with increased DNA methylation in SK-N-BE neuroblastoma cell line.
Cells (2024) 13(1):58. https://doi.org/10.3390/cells13010058
With press release (attached to the online pdf)
$IF_{2023} = 5.1$

2) Kleinfelder K., Lotti V., Eramo A., Amato F., Lo Cicero S., Castelli G., Spadaro F., Farinazzo A., Dell'Orco D., Preato S., Conti J., Rodella L., Tomba F., Cerofolini A., Baldisseri E., Bertini M., Volpi S., Villella V.R., Esposito S., Zollo I., Castaldo G., Laudanna C., Sorsher E.J., Hong J., Joshi D., Cutting G., **Lucarelli M.**, Melotti P., Sorio C.
In silico analysis and theratyping of an ultra-rare CFTR genotype (W57G/A234D) in primary human rectal and nasal epithelial cells.
iScience (2023) 26(11):108180. https://doi.org/10.1016/j.isci.2023.108180
$IF_{2023} = 4.6$

3) Lo Cicero S., Castelli G., Blaconà G. Bruno S.M., Sette G., Pigliucci R., Villella V.R., Esposito S., Zollo I., Spadaro F., De Maria R., Biffoni M., Cimino G., Amato F., **Lucarelli M.**, Eramo A. (**Lucarelli** and Eramo **co-last Authors**)
L1077P CFTR pathogenic variant function rescue by Elexacaftor-Tezacaftor-Ivacaftor in cystic fibrosis patient-derived air-liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients.
Respiratory Research (2023) 24:217. https://doi.org/10.1186/s12931-023-02516-0
$IF_{2023} = 4.7$

4) Raia T., Armeli F., Cavallaro R.A., Ferraguti G., Businaro R., **Lucarelli M.**, Fuso A. (**Lucarelli** and Fuso **co-last Authors**)
Perinatal S-adenosylmethionine supplementation represses PSEN1 expression by the cellular epigenetic memory of CpG and non-CpG methylation in adult TgCRD8 mice.
International Journal of Molecular Sciences (2023) 24(14):11675. https://doi.org/10.3390/ijms241411675
$IF_{2023} = 4.9$

5) Fiore M., Minni A., Cavalcanti L., Raponi G., Puggioni G., Mattia A., Gariglio S., Colizza A., Meliante P.G., Zoccali F., Tarani L., Barbato C., **Lucarelli M.**, Ceci F.M., Francati S., Ferraguti G., Ceccanti M., Petrella C.
The impact of alcohol consumption and oral microbiota on upper aerodigestive tract carcinomas: a pilot study.
Antioxidants (Basel) (2023) 12(6):1233. https://dx.doi.org/10.3390/antiox12061233
$IF_{2023} = 6.0$

6) Miglione A., Raucci A., Amato J., Marzano S., Pagano B., Raia T., **Lucarelli M.**, Fuso A., Cinti S.
Printed electrochemical strip for the detection of miRNA-29a: a possible biomarker related to Alzheimer's disease.
Analytical Chemistry (2022) 94(45):15558-15563 https://doi.org/10.1021/acs.analchem.2c03542
With press release (attached to the online pdf)
$IF_{2022} = 7.4$

7) Blaconà G., Raso R., Castellani S., Pierandrei S., Del Porto P., Ferraguti G., Ascenzioni F., Conese M., **Lucarelli M.**
Downregulation of Epithelial Sodium Channel (ENaC) activity in cystic fibrosis cells by epigenetic targeting.
Cellular and Molecular Life Sciences (2022) 79(5):257-274. https://doi.org/10.1007/s00018-022-04190-9
$IF_{2022} = 8.0$

8) Sette G., Lo Cicero S., Blaconà G., Pierandrei S., Bruno S.M., Salvati V., Castelli G., Falchi M., Fabrizzi B., Cimino G., De Maria R., Biffoni M., Eramo A., **Lucarelli M.**
Theratyping cystic fibrosis *in vitro* in ALI-culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells.
European Respiratory Journal (2021) 58(6):2100908. https://doi.org/10.1183/13993003.00908-2021
With Editorial https://doi.org/10.1183/13993003.02735-2021 **and press release** (both attached to the online pdf)
$IF_{2021} = 33.809$

9) Farina A., Labriola R., Ialongo C, Suppa M., Viggiani V., **Lucarelli M.**, Anastasi E., Angeloni A.
Transient plasma cell dyscrasia in COVID-19 patients linked to IL-6 triggering.
Microbes and Infection (2021) 23(4-5):104808. https://doi.org/10.1016/j.micinf.2021.104808
$IF_{2021} = 9.570$

10) Pierandrei S., Truglio G., Ceci F., Del Porto P., Bruno S.M., Castellani S., Conese M., Ascenzioni F., **Lucarelli M.**
DNA methylation patterns correlate with the expression of SCNN1A, SCNN1B and SCNN1G (epithelial sodium channel, ENaC) genes.
International Journal of Molecular Sciences (2021) 22(7):3754(1-14). https://doi.org/10.3390/ijms22073754
$IF_{2021} = 6.208$

11) Sterrantino M., Fuso A., Pierandrei S., Bruno S.M., Testino G., Cimino G., Angeloni A., **Lucarelli M.**
Quantitative evaluation of CFTR pre-mRNA splicing dependent on the (TG)mTn poly-variant tract.
Diagnostics (2021) 11(2):168(1-11). https://doi.org/10.3390/diagnostics11020168
$IF_{2021} = 3.992$

12) Lucarelli M., Porcaro L., Biffignandi A., Costantino L., Giannone V., Alberti L., Bruno S.M., Corbetta C., Torresani E., Colombo C., Seia M.
A new targeted CFTR mutation panel based on next generation sequencing technology.
Journal of Molecular Diagnostics (2017) 19(5):788-800. https://doi.org/10.1016/j.jmoldx.2017.06.002
$IF_{2017} = 4.880$

13) Terlizzi V., Castaldo G., Salvatore D., **Lucarelli M.**, Raia V., Angioni A., Carnovale V., Cirilli N., Casciaro R., Colombo C., Di Lullo A.M., Elce A., Iacotucci P., Comegna M., Scorza M., Lucidi V., Perfetti A., Cimino R., Quattrucci S., Seia M., Sofia V.M., Zarrilli F., Amato F.
Genotype-phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles.
Journal of Medical Genetics (2017) 54(4):224-235. https://doi.org/10.1136/jmedgenet-2016-103985
$IF_{2017} = 5.751$

14) Lucarelli M., Bruno S.M., Pierandrei S., Ferraguti G., Testino G., Truglio G., Strom R., Quattrucci S.
The impact on genetic testing of mutational patterns of CFTR gene in different clinical macrocategories of cystic fibrosis.
Journal of Molecular Diagnostics (2016) 18(4):554-565. https://doi.org/10.1016/j.jmoldx.2016.02.007
$IF_{2016} = 4.526$

15) Pierandrei S., Luchetti A., Sanchez M., Novelli G., Sangiuolo F., **Lucarelli M.**
The gene targeting approach of Small Fragment Homologous Replacement (SFHR) alters the expression patterns of DNA repair and cell cycle control genes.
Molecular Therapy Nucleic Acids (2016) 5:e304. https://doi.org/10.1038/mtna.2016.2
$IF_{2016} = 6.392$

16) Lucarelli M., Bruno S.M., Pierandrei S., Ferraguti G., Stamato A., Narzi F., Amato A., Cimino G., Bertasi S., Quattrucci S., Strom R.
A genotypic-oriented view of CFTR genetics highlights specific mutational patterns underlying clinical macro-categories of cystic fibrosis.
Molecular Medicine (2015) 21:257-275. https://doi.org/10.2119/molmed.2014.00229
$IF_{2015} = 3.530$

List of further 45 publications in international journals with IF > 3, selected for the individual evaluation, numbered from 17 to 61

17) Occhiuto M., Pepe J., Colangelo L., **Lucarelli M.**, Angeloni A., Nieddu L., De Martino V., Minisola S., Cipriani C.
Effect of 2 years of monthly calcifediol administration in postmenopausal women with vitamin D insufficiency
Nutrients (2024) 16(11):1754. https://doi.org/10.3390/nu16111754
$IF_{2023} = 4.8$

18) Terracina S., Tarani L., Ceccanti M., Vitali M., Francati S., **Lucarelli M.**, Venditti S., Verdone L., Ferraguti G., Fiore M.
The impact of oxidative stress on the epigenetics of fetal alcohol spectrum disorders
Antioxidants (Basel) (2024) 13(4):410. https://doi.org/10.3390/antiox13040410
$IF_{2023} = 6.0$

19) Paparella R., Ferraguti G., Fiore M., Menghi M., Micangeli G., Tarani F., Ligotino A., Messina M.P, Ceccanti M., Minni A., Barbato C., **Lucarelli M.**, Tarani L., Petrella C.
Serum Lipocalin-2 levels as biomarker in pre- and post-pubertal Klinefelter syndrome patients: a pilot study
International Journal of Molecular Sciences (2024) 25(4):2214 https://doi.org/10.3390/ijms25042214
$IF_{2023} = 4.9$

20) Ceci F.M., Ferraguti G., **Lucarelli M.**, Angeloni A., Bonci E., Petrella C., Francati S., Barbato C., Di Certo M.G., Gabanella F., Gavaruzzi F., Mastroianni C.M., Minni A., Greco A., Ralli M., Ceccanti M., Tarani L., Fiore M.
Investigating biomarkers for COVID-19 morbidity and mortality.
Current Topics in Medicinal Chemistry (2023) 23(13):1196-1210. https://doi.org/10.2174/1568026623666230222094517
$IF_{2023} = 2.9$

21) Terracina S., Pallaria A., **Lucarelli M.**, Angeloni A., De Angelis A., Ceci F.M., Caronti B., Francati S., Blaconà G., Fiore M., Ferraguti G.
Urine dipstick analysis on automated platforms: is a reliable screening tool for proteinuria? An experience from Umberto I Hospital in Rome.
Biomedicines (2023) 11(4):1174. https://doi.org/10.3390/biomedicines11041174
$IF_{2023} = 3.9$

22) Pennacchia F., Rusi E., Ruqa W.A., Zingaropoli M.A., Pasculli P., Talarico G., Bruno G., Barbato C., Minni A., Tarani L., Galardo G., Pugliese F., **Lucarelli M.**, Ferraguti G., Ciardi M.R., Fiore M.
Blood biomarkers from the emergency department disclose severe omicron COVID-19-associated outcomes.
Microorganisms (2023) 11(4):925. https://doi.org/10.3390/microorganisms11040925
$IF_{2023} = 4.1$

23) Conflitti A.C., Cicolani G., Buonacquisto A., Pallotti F., Faja F., Bianchini S., Blaconà G., Bruno S.M., Linari A., **Lucarelli M.**, Montanino D., Muzii L., Lenzi A., Lombardo F., Paoli D.
Sperm DNA fragmentation and sperm-borne miRNAs: molecular biomarkers of embryo development?
International Journal of Molecular Sciences (2023) 24(2):1007. https://doi.org/10.3390/ijms24021007
$IF_{2023} = 4.9$

24) Ferraguti G., Terracina S., Micangeli G., **Lucarelli M.**, Tarani L., Ceccanti M., Spaziani M., D'Orazi V., Petrella C., Fiore M.
NGF and BDNF in pediatrics syndromes.
Neuroscience and biobehavioral reviews (2023) 145:105015. https://doi.org/doi:10.1016/j.neubiorev.2022.105015
$IF_{2023} = 7.5$

25) Terracina S., Petrella C., Francati S., **Lucarelli M.**, Barbato C., Minni A., Ralli M., Greco A., Tarani L., Fiore M., Ferraguti G.
Antioxidant intervention to improve cognition in the aging brain: The example of hydroxytyrosol and resveratrol.
International Journal of Molecular Sciences (2022) 23(24):15674 https://doi.org/10.3390/ijms232415674
$IF_{2022} = 5.6$

26) Tosco A., Castaldo A., Colombo C., Claut L., Carnovale V., Iacotucci P., **Lucarelli M.**, Cimino G. Fabrizzi B., Caporelli N., Majo F., Ciciriello F., Padoan R., Poli P., Taccetti G., Centrone C., Casciaro R., Castellani C., Salvatore D., Colangelo C., Bonomi P., Castaldo G., Terlizzi V.
Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype
Journal Cystic Fibrosis (2022) 21(5):850-855 https://doi.org/10.1016/j.jcf.2022.04.020
$IF_{2022} = 5.2$

27) Terracina S., Ferraguti G., Tarani L., Messina M.P., **Lucarelli M.**, Vitali M., De Persis S., Greco A., Minni A., Polimeni A., Ceccanti M., Petrella C., Fiore M.
Transgenerational abnormalities induced by paternal preconceptual alcohol drinking: findings from humans and animal models.
Current Neuropharmacology (2022) 20(6):1158-1173. https://doi.org/10.2174/1570159X19666211101111430
$IF_{2022} = 5.3$

28) Ceci F.M., Fiore M., Agostinelli E., Tahara T., Greco A., Ralli M., Polimeni A., **Lucarelli M.**, Colletti R., Angeloni A., Tirassa P., Ceccanti M., Messina M.P., Vitali M., Petrella C., Ferraguti G.
Urinary ethyl glucuronide for the assessment of alcohol consumption during pregnancy: Comparison between biochemical data and screening questionnaires.
Current Medicinal Chemistry (2022) 29(17):3125-3141. https://doi.org/10.2174/0929867328666211125100329
$IF_{2022} = 4.1$

29) Ceci F.M., Fiore M., Gavaruzzi F., Angeloni A., **Lucarelli M.**, Scagnolari C., Bonci E., Gabanella F., Di Certo M.G., Barbato C., Petrella C., Greco A., De Vincentiis M., Ralli M., Passananti C., Poscia R., Minni A., Ceccanti M., Tarani L., Ferraguti G.
Early routine biomarkers of SARS-CoV-2 morbidity and mortality: Outcomes from an emergency section.
Diagnostics (Basel) (2022) 12(1):176. https://doi.org/10.3390/diagnostics12010176
$IF_{2022} = 3.6$

30) Ferraguti G., Terracina S., Petrella C., Greco A., Minni A., **Lucarelli M.**, Agostinelli E., Ralli M., de Vincentiis M., Raponi G., Polimeni A., Ceccanti M., Caronti B., Di Certo M.G., Barbato C., Mattia A., Tarani L., Fiore M.
Alcohol and head and neck cancer: Updates on the role of oxidative stress, genetic, epigenetics, oral microbiota, antioxidants, and alkylating agents.

Antioxidants (Basel) (2022) 11(1):145. https://doi.org/doi:10.3390/antiox11010145
$IF_{2022} = 7.0$

31) Ferlito C., Visco V., Biselli R., Cattaruzza M.S., Carreras G., Salerno G., Lista F., Capobianchi M.R., Castilletti C., Lapa D., Antonelli G., Gentile M., Sorice M., Riitano G., Lucania G., Riccieri V., Mainiero F., Angeloni A., **Lucarelli M.**, Ferraguti G., Autore A., Lastilla M., Salemi S., Biondo M.I., Picchianti-Diamanti A., Caporuscio S., Teloni R., Mariotti S., Nisini R., D'Amelio R.
Safety of multiple vaccinations and durability of vaccine-induced antibodies in an Italian military cohort 5 years after immunization.
Biomedicines (2022) 10(1):6. https://doi.org/10.3390/biomedicines10010006
$IF_{2022} = 4.7$

32) Petrella C., Di Certo M.G, Gabanella F., Barbato C., Ceci F.M., Greco A., Ralli M., Polimeni A., Angeloni A., Severini C., Vitali M., Ferraguti G., Ceccanti M., **Lucarelli M.**, Severi C., Fiore M.
Mediterranean diet, brain and muscle: olive polyphenols and resveratrol protection in neurodegenerative and neuromuscular disorders.
Current Medicinal Chemistry (2021) 28(37):7595-7613. https://doi.org/10.2174/0929867328666210504113445
$IF_{2021} = 4.740$

33) Terlizzi V., Claut L., Tosco A., Colombo C., Raia V., Fabrizzi B., **Lucarelli M.**, Angeloni A., Cimino G., Castaldo A., Marsiglio L., Timpano S., Cirilli N., Moroni L., Festini F., Piccinini P., Zavataro L., Bonomi P., Taccetti G., Southern K., Padoan R.
A survey of the prevalence, management and outcome of infants with an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis (CRMS/CFSPID) in six Italian centres.
Journal of Cystic Fibrosis (2021) 20(5):828-834. https://doi.org/10.1016/j.jcf.2021.03.015
$IF_{2021} = 5.527$

34) Terlizzi V., Claut L., Colombo C., Tosco A., Castaldo A., Fabrizzi B., **Lucarelli M.**, Cimino G., Carducci C., Dolce D., Biffi A., Bonomi P., Timpano S., Padoan R.
Outcomes of early repeat sweat testing in infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome / CF screen-positive, inconclusive diagnosis.
Pediatric Pulmonology (2021) 56(12):3785-3791. https://doi.org/10.1002/ppul.25683
$IF_{2021} = 4.090$

35) Terlizzi V., Padoan R., Claut L., Colombo C., Fabrizzi B., **Lucarelli M.**, Bruno S.M., Castaldo A., Bonomi P., Taccetti G., Tosco A.
CRMS/CFSPID subjects carrying D1152H CFTR variant: can the second variant be a predictor of disease development?
Diagnostics (2020) 10(12):1080(1-10). https://doi.org/10.3390/diagnostics10121080
$IF_{2020} = 3.706$

36) Monti N., Cavallaro R., Stoccoro A., Nicolia V., Scarpa S., Kovacs G.G., Fiorenza M.T., **Lucarelli M.**, Aronica E., Ferrer I., Coppedè F., Troen A.M., Fuso A.
CpG and non-CpG Presenilin1 methylation pattern in course of neurodevelopment and neurodegeneration is associated with gene expression in human and murine brain.
Epigenetics (2020) 15(8):781-799. https://doi.org/10.1080/15592294.2020.1722917
With press release 1 https://newsroom.taylorandfrancisgroup.com/could-new-discovery-play-a-role-in-diagnosing-alzheimers-earlier/?_ga=2.209892949.1799144815.1721057689-1539162900.1721057689
With press release 2 https://www.uniroma1.it/it/notizia/alzheimer-un-nuovo-biomarker-la-diagnosi
$IF_{2020} = 4.528$

37) Fuso A., Raia T., Orticello M., **Lucarelli M**.
The complex interplay between DNA methylation and miRNAs in gene expression regulation.
Biochimie (2020) 173:12-16. https://doi.org/10.1016/j.biochi.2020.02.006
$IF_{2020} = 4.079$

38) Scribano D., Sarshar M., Prezioso C., **Lucarelli M.**, Angeloni A., Zagaglia C., Palamara A.T., Ambrosi C.
d-Mannose treatment neither affects Uropathogenic *Escherichia coli* properties nor induces stable FimH modifications.

Molecules (2020) 25(2):316. https://doi.org/10.3390/molecules25020316
$IF_{2020} = 4.411$

39) Lucarelli M., Ferraguti G., Fuso A.
Active demethylation of non-CpG moieties in animals: a neglected research area.
International Journal of Molecular Sciences (2019) 20(24):6272. https://doi.org/10.3390/ijms20246272
$IF_{2019} = 4.556$

40) Cosentino L., Vigli D., Medici V., Flor H., **Lucarelli M.**, Fuso A., De Filippis B.
Methyl-CpG binding protein 2 functional alterations provide vulnerability to develop behavioral and molecular features of post-traumatic stress disorder in male mice.
Neuropharmacology (2019) 160:107664. https://doi.org/10.1016/j.neuropharm.2019.06.003
$IF_{2019} = 4.431$

41) Pipolo S., Puglisi R., Mularoni V., Esposito V., Fuso A., **Lucarelli M.**, Fiorenza M.T., Mangia F., Boitani C.
Involvement of sperm acetylated histones and the nuclear isoform of Glutathione Peroxidase 4 in fertilization.
Journal of Cellular Physiology (2018) 233(4):3093-3104. https://doi.org/10.1002/jcp.26146
$IF_{2018} = 4.522$

42) Ceccanti M., Cambieri C., Frasca V., Onesti E., Biasotta A., Giordano C., Bruno S.M., Testino G., **Lucarelli M.**, Arca M., Inghilleri M.
A novel mutation in ABCA1 gene causing Tangier Disease in an Italian family with uncommon neurological presentation.
Frontiers in Neurology (2016) 7:1-7. https://doi.org/10.3389/fneur.2016.00185
$IF_{2016} = 3.552$

43) Montali A., Truglio G., Martino F., Ceci F., Ferraguti G., Ciociola E., Maranghi M., Gianfagna F., Iacoviello L., Strom R., **Lucarelli M.**, Arca M.
Atherogenic dyslipidemia in children: evaluation of clinical, biochemical and genetic aspects
PLoS One (2015) 10(4):e0120099:1-13. https://doi.org/10.1371/journal.pone.0120099
$IF_{2015} = 3.057$

44) Fuso A., Ferraguti G., Scarpa S., Ferrer I., **Lucarelli M.**
Disclosing bias in bisulfite assay: "*MethPrimers*" underestimate high DNA methylation.
PLoS One (2015) 10(2)e0118318:1-12. https://doi.org/10.1371/journal.pone.0118318
With press release
https://www.google.com/url?q=https://www.uniroma1.it/sites/default/files/allegati_news/rassegna%2520stampa%2520ok.pdf&source=gmail-imap&ust=1721726065000000&usg=AOvVaw2bFrHPlXan76f17XNFlLcV
$IF_{2015} = 3.057$

45) Terlizzi V., Carnovale V., Castaldo G., Castellani C., Cirilli N., Colombo C., Corti F., Cresta F., D'Adda A., **Lucarelli M.**, Lucidi V., Macchiaroli A., Madarena E., Padoan R., Quattrucci S., Salvatore D., Zarrilli F., Raia V.
Clinical expression of patients with the D1152H CFTR mutation.
Journal of Cystic Fibrosis (2015) 14:447-452. https://doi.org/10.1016/j.jcf.2014.12.012
$IF_{2015} = 3.853$

46) Nicolia V., **Lucarelli M.**, Fuso A.
Environment, epigenetics and neurodegeneration: Focus on nutrition in Alzheimer's disease.
Experimental Gerontology (2015) 68:8-12. https://doi.org/10.1016/j.exger.2014.10.006
$IF_{2015} = 3.350$

47) Ferraguti G., Pascale E., **Lucarelli M.**
Alcohol addiction: a molecular biology perspective
Current Medicinal Chemistry (2015) 22(6):670-684. https://doi.org/10.2174/0929867321666141229103158
$IF_{2015} = 3.455$

48) Schippa S., Iebba V., Santangelo F., Gagliardi A., De Biase R.V., Stamato A., Bertasi S., **Lucarelli M.**, Conte M.P., Quattrucci S.
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) allelic variants relate to shifts in faecal microbiota of Cystic Fibrosis patients.
PLoS One (2013) 8(4): e61176. https://doi.org/10.1371/journal.pone.0061176
$IF_{2013} = 3.534$

49) Luchetti A., Filareto A., Sanchez M., Ferraguti G., Lucarelli M., Novelli G., Sangiuolo F., Malgieri A.
Small Fragment Homologous Replacement: evaluation of factors influencing modification efficiency in an eukaryotic assay system.
PLoS One (2012) 7(2):e30851 https://doi.org/10.1371/journal.pone.0030851
$IF_{2012} = 3.730$

50) Fuso A., Ferraguti G., Grandoni F., Ruggeri R., Scarpa S., Strom R., **Lucarelli M.**
Early demethylation of non-CpG, CpC-rich, elements in the myogenin 5'-flanking region: a priming effect on the spreading of active demethylation.
Cell Cycle (2010) 9(19):3965-3976. https://doi.org/10.4161/cc.9.19.13193
With comment https://doi.org/10.4161/cc.9.19.13563
$IF_{2010} = 4.999$

51) Lucarelli M., Narzi L., Pierandrei S., Bruno S.M., Stamato A., d'Avanzo M., Strom R., Quattrucci S.
A new complex allele of the CFTR gene partially explains the variable phenotype of the L997F mutation.
Genetics in Medicine (2010) 12(9):548-555. https://doi.org/10.1097/GIM.0b013e3181ead634
$IF_{2010} = 5.280$

52) Auriche C., Di Domenico E.G., Pierandrei S., **Lucarelli M.**, Castellani S., Conese M., Melani R., Zegarra-Moran O., Ascenzioni F.
CFTR expression and activity from the human CFTR locus in BAC vectors, with regulatory regions, isolated by a single step procedure.
Gene Therapy (2010) 17(11):1341-1354. https://doi.org/10.1038/gt.2010.89
$IF_{2010} = 4.538$

53) Narzi L., Ferraguti G., Stamato A., Narzi F., Valentini S.B., Lelli A., Delaroche I., **Lucarelli M.**, Strom R., Quattrucci S.
Does cystic fibrosis neonatal screening detect atypical CF forms? Extended genetic characterization and 4-year clinical follow-up.
Clinical Genetics (2007) 72(1):39–46. https://doi.org/10.1111/j.1399-0004.2007.00825.x
$IF_{2007} = 3.181$

54) Rossi T., Grandoni F., Mazzilli F., Quattrucci S., Antonelli M., Strom R., **Lucarelli M**.
High frequency of $(TG)_mT_n$ variant tracts in the cystic fibrosis transmembrane conductance regulator gene in men with high semen viscosity.
Fertility and Sterility (2004) 82(5):1316-22. https://doi.org/10.1016/j.fertnstert.2004.03.065
$IF_{2004} = 3.170$

55) Lucarelli M., Borrelli V., Fiori A., Cucina A., Granata F., Potenza R.L., Scarpa S., Cavallaro A., Strom R. The expression of native and oxidized LDL receptors in brain microvessels is specifically enhanced by astrocytes-derived soluble factor(s).
FEBS Letters (2002) 522(1-3):19-23. https://doi.org/10.1016/s0014-5793(02)02857-0
$IF_{2002} = 3.912$

56) Lucarelli M., Fuso A., Strom R., Scarpa S.
The dynamics of myogenin site-specific demethylation is strongly correlated with its expression and with muscle differentiation.
The Journal of Biological Chemistry (2001) 276(10):7500-7506. https://doi.org/10.1074/jbc.M008234200
$IF_{2001} = 7.258$

57) Cucina A., Corvino V., Sapienza P., Borrelli V., **Lucarelli M.**, Scarpa S., Strom R., Santoro-D'angelo L., Cavallaro A.
Nicotine regulates basic fibroblastic growth factor and transforming growth factor beta1 production in endothelial cells.
Biochemical and Biophysical Research Communications (1999) 257(2):306-312. https://doi.org/10.1006/bbrc.1999.0478
$IF_{1999} = 3.161$

58) Minotti S., Scicchitano B.M., Nervi C., Scarpa S., **Lucarelli M.**, Molinaro M., Adamo S.
Vasopressin and insulin-like growth factors synergistically induce myogenesis in serum-free medium.
Cell Growth and Differentiation (1998) 9(2):155-164.
$IF_{1998} = 4.269$

59) Lucarelli M., Gennarelli M., Cardelli P., Novelli G., Scarpa S., Dallapiccola B., Strom R.
Expression of receptors for native and chemically modified low-density lipoproteins in brain microvessels.
Febs Letters (1997) 401(1):53-58. https://doi.org/10.1016/s0014-5793(96)01435-4
$IF_{1997} = 3.263$

60) Lucarelli M., Palitti F., Carotti D., Cianfriglia M., Signoretti C., Bozzi A., Strom R.
AZT-induced hypermethylation of human thymidine kinase gene in the absence of total DNA hypermethylation.
Febs Letters (1996) 396(2-3):323-326. https://doi.org/10.1016/0014-5793(96)01124-6
$IF_{1996} = 3.504$

61) Scarpa S., **Lucarelli M.**, Palitti F., Carotti D., Strom R.
Simultaneous myogenin expression and overall DNA hypomethylation promote in vitro myoblast differentiation.
Cell Growth and Differentiation (1996) 7(8):1051-1058.
$IF_{1996} = 3.535$

Guidelines, Consensus, Position papers

62) Lucarelli M. (coordinatore), Angioni A., Baffico M., Bombieri C., Bonizzato A., Borgo G., Castaldo G., Castellani C., Centrone C., Coiana A., D'Apice M.R., Di Girgenti C., Egiziano S., Favarato M., Ferlisi A., Melotti P., Minicucci L., Pelo E., Ragusa A., Ravani A., Savoldi G., Seia M., Termini L.
Consensus 2019 per l'analisi genetica in Fibrosi Cistica. Documento congiunto SIFC, SIAMS, SIBIOC, SIGU
Con presentazione del documento in Biochimica Clinica (2020) 44(4):397 – 399.
https://doi.org/10.19186/BC_2020.074 e link ai website di SIFC, SIBIOC, SIGU
Documentazione completa in file allegato in Titoli N. 1

63) Assael B.M., Baffico M., Centrone C., Colombo C., Castaldo G., Castellani C., Di Girgenti C., **Lucarelli M.**, Lucidi V., Minicucci L., Padoan R., Perobelli S., Raia V., Repetto T., Santostasi T., Seia M., Stamato A., Termini L., Zappa C.
Raccomandazioni sul test del portatore di mutazioni del gene CFTR (2013) (Documento SIFC).
Documentazione in file allegato in Titoli N. 8

Books and book chapters

64) Rossi T., Mazzilli F., Strom R., **Lucarelli M.**
Infertilità maschile e CFTR.
Pubblicazione elettronica sul Sito del Ministero della Salute:
www.salute.gov.it/resources/static/focus/307/testo_completo.pdf
In "Patologie andrologiche dell'età giovanile: il ruolo della prevenzione" (2004) pp. 125-137. ***(book chapter)***

65) Lucarelli M., Narzi L.
Aspetti genetici della fibrosi cistica.
In "Cardiologia e pneumologia", CEPI (gruppo AIM) editore (2000) pp. 9-15. ***(book chapter)***

66) Lucarelli M., Pierandrei S., Bruno S.M., Strom R.
The genetics of CFTR: genotype – phenotype relationship, diagnostic challenge and therapeutic implications. In "Cystic Fibrosis – Renewed hopes through research", Intech open access publisher (2012) Chap. 5, pp. 91 – 122. https://www.intechopen.com/chapters/34279 ***(book chapter)***

67) Natale M.P., Miceli S., Alterio G., Bressan G., Cabrini A., Castelli G., De Villa, S., Di Renzo A., D'Onofrio I., Fabrizio F.P., Fasson C., **Lucarelli M.**, Martino M., Mistretta A.L., Muscarella L.A., Muzi G., Pagano F., Qualtieri K., Scaramuzzino I., Virgili R.
I test dei concorsi per tecnico di laboratorio biomedico.
Edizioni Edises (I edizione 2017; II edizione 2021; III edizione 2024). ***(book)***

Popular articles and comments

68) Lucarelli M.
Commento all'articolo "Triple therapy for cystic fibrosis Phe508del –gating and –residual function genotypes"
Orizzonti FC (Organo della Società Italiana per lo studio della Fibrosi Cistica) (2021), 18(3), pp. 28-31.

69) Lucarelli M.
Riflessioni su una possibile convergenza tra LIFC FFC e SIFC.
Orizzonti FC (Organo della Società Italiana per lo studio della Fibrosi Cistica) (2017), 14(1), pp. 4-5.

70) Lucarelli M.
Scelte procreative e mutazioni di significato incerto.
Orizzonti FC (Organo della Società Italiana per lo studio della Fibrosi Cistica) (2016), 13(1), pp. 33-34.

71) Lucarelli M.
Screening del "portatore": alcune riflessioni.
Orizzonti FC (Organo della Società Italiana per lo studio della Fibrosi Cistica) (2012), 9(1), pp. 25-26.

72) Lucarelli M.
Una nuova strategia per correggere le mutazioni di splicing.
Newsletter Fondazione per la ricerca sulla fibrosi cistica (2012) n. 111.

73) Lucarelli M.
Nuova via per correggere l'effetto delle mutazioni di stop.
Newsletter Fondazione per la ricerca sulla fibrosi cistica (2011) n. 100.

74) Lucarelli M.
Novità sulla genetica molecolare applicata alla diagnostica della Fibrosi Cistica.
Notiziario della Fondazione per la Ricerca sulla Fibrosi Cistica (2005) n. 13, pp. 20-21.

Roma, 19/7/2024

IN FEDE
MARCO LUCARELLI